01 What is Thymosin Alpha-1?
In plain English.
Thymosin Alpha-1 is a lab-made copy of a small peptide your thymus naturally makes. The thymus is the gland that trains your T cells, the part of the immune system that targets virus-infected cells and tumours. The synthetic version (sold as Zadaxin, with the generic name thymalfasin) is one of the most-prescribed peptide immunomodulators in the world, but its approval map is unusually patchwork: licensed in roughly 35 countries, including Italy, China, parts of Latin America and South-East Asia, primarily as an add-on for chronic viral hepatitis. It is not licensed by the FDA in the United States, the EMA in the EU, or the MHRA in the UK. Outside its approved indications it is widely marketed as a general 'immune booster', for that use, the evidence is essentially zero.
Thymosin Alpha-1 was the first peptide isolated from Goldstein's thymosin fraction 5 in the 1970s, sequenced in 1977 (Goldstein et al., PNAS), and developed as Zadaxin by SciClone Pharmaceuticals. The approval picture is genuinely asymmetric. It is on-label in countries that cover most of the world's chronic-hepatitis-B burden, yet was never approved by the FDA or EMA, the US and European regulators have not been convinced by the trial package. That asymmetry, not the molecule itself, is the most important thing to understand about Tα1.
02 How it works
The simple version, then the science.
Thymosin Alpha-1 nudges the T-cell side of the immune system. It encourages T-cell precursors to mature into functional T cells, increases the activity of natural killer (NK) cells, and helps dendritic cells present pathogen and tumour signals to the rest of the immune system. The effect is immunomodulatory rather than directly antiviral, Tα1 does not attack hepatitis B or any other virus directly; it improves the body's ability to mount a response against virus-infected cells. That is also why it is used as an adjunct to interferon in hepatitis trials, rather than as a stand-alone antiviral.
Go deeper · the proposed mechanism
Tα1 is a 28-amino-acid acidic peptide identical to the N-terminal fragment of prothymosin alpha. Mechanistically it signals through Toll-like receptors, principally TLR2, TLR9 and TLR4, on dendritic cells, monocytes and T cells, activating MyD88-dependent NF-κB and IRF signalling. The downstream effects include enhanced dendritic-cell maturation and antigen presentation, increased IL-2 and IFN-γ production, expansion of CD4+ and CD8+ T-cell populations, increased NK-cell cytotoxicity, and a shift toward a Th1 cytokine profile. Plasma half-life after subcutaneous dosing is short (~2 hours), but the downstream cellular effects outlast the drug itself. Receptor binding is selective for the TLR family; it has no meaningful activity at the growth-hormone or sex-hormone axes, so it is mechanistically unrelated to the GHRH/GHRP peptides it sometimes shares a shelf with.
03 What it's used for
Each use graded by how strong the evidence actually is.
- ApprovedChronic hepatitis B (in approved countries)Approved as Zadaxin in ~35 countries, including Italy, China and across South-East Asia, for chronic hepatitis B, as monotherapy or combined with interferon-alpha or nucleoside analogues. Yang et al. (Antiviral Research, 2008) meta-analysed four RCTs (199 patients) and reported delayed-but-sustained virological and biochemical response advantages versus interferon-alpha at six months post-treatment. NOT an FDA/EMA/MHRA indication.
- ApprovedChronic hepatitis C, adjunct to interferon (in approved countries)Approved in several Zadaxin countries as an add-on to interferon-alpha (and historically ribavirin) for chronic hepatitis C. The clinical relevance of this indication has shrunk dramatically since direct-acting antivirals (sofosbuvir-based regimens) became standard of care for HCV worldwide. NOT an FDA/EMA/MHRA indication.
- ModerateSevere sepsis, immunomodulationMostly studied in China. A 2016 BMC Infectious Diseases systematic review (Liu et al., 19 RCTs in 1,225 patients) found Tα1 was associated with reduced 28-day mortality and improved immune markers in severe sepsis, but rated the evidence quality as low. Multiple later meta-analyses point in the same direction. Not an FDA-approved indication anywhere.
- LimitedCOVID-19, used in China, signal is mixedTα1 was used clinically in China during the early COVID-19 pandemic for severe cases. The largest study, Liu et al. (Frontiers in Immunology, 2021), a multicentre cohort of 2,282 patients across five Hubei hospitals, actually associated Tα1 use with a higher non-recovery rate (21.2% vs 14.6%), particularly when started late in severe disease. Smaller observational studies were more positive. No large RCT settled the question, and major Western guidelines never recommended it for COVID.
- LimitedCancer adjunct (selected indications)In some approved-Zadaxin countries Tα1 is used alongside chemotherapy for selected solid tumours (notably hepatocellular carcinoma, melanoma and non-small-cell lung cancer). The supporting trial literature is patchy and largely sponsor-linked; results have not been replicated to FDA/EMA standards.
- Anecdotal"Immune boost" / chronic infection / long COVID / general wellnessThe dominant off-label use case in the West. There are no Phase 3 trials of Tα1 for "boosting" a healthy immune system, treating chronic Lyme, treating long COVID, or any of the related wellness positionings. Any reported effect rests on testimony and mechanistic extrapolation from the approved indications, not on direct evidence.
04 What the evidence says
The evidence base is real but mixed. The strongest signal is in chronic hepatitis B: Yang et al. (Antiviral Research, 2008) meta-analysed four randomised trials comparing Tα1 to interferon-alpha and reported delayed-but-sustained advantages on virological, biochemical and complete response six months after the end of therapy, the benefit was not immediately visible at end-of-treatment but accumulated afterwards. Combination meta-analyses (Tα1 + lamivudine, Tα1 + entecavir) suggest additive benefit over nucleoside monotherapy on ALT normalisation and HBeAg seroconversion. Outside hepatitis the picture thins: in sepsis, the 2016 BMC Infectious Diseases systematic review and several Chinese meta-analyses point to a mortality and immune-marker benefit, but the underlying trials are rated low-quality and almost all are from one geography. In COVID-19, the largest cohort study (Liu et al., Frontiers in Immunology 2021, n=2,282) actually associated Tα1 with a higher non-recovery rate in severely-ill patients, particularly when started late, a sobering counter to early enthusiasm. Honest caveats: most trials are Chinese, many are sponsor- or hospital-funded, blinding is inconsistent, the FDA and EMA have not been satisfied by this package, and the gap between the approved indications and the marketed off-label uses (general immunity, long COVID, anti-ageing) is wide.
05 Dosing & administration
Reported in the literature, information not advice.
For information only, Thymosin Alpha-1 is a prescription medicine in the countries that license it, and dosing should be set by a clinician familiar with the approved indication, not by reading a webpage. The standard Zadaxin schedule in chronic hepatitis B is 1.6 mg by subcutaneous injection twice weekly, typically for six months when used as monotherapy or alongside interferon. Sepsis and cancer-adjunct protocols vary by indication and centre. Off-label "immune boost" protocols seen in private clinics and the research-chemical channel (often 1.5 mg daily or every other day for several weeks) have not been validated in any Western trial and do not map onto how the licensed product is used in approved countries. This is not an instruction to dose: outside the ~35 approved-Zadaxin markets there is no licensed supply route, the research-chemical channel is unverified for identity and purity, and clinician oversight is the floor for any responsible use.
06 Side effects & safety
Tα1 has a relatively benign side-effect profile in the trial literature, generally tolerated about as well as placebo on most endpoints. The commonest adverse events are local injection-site reactions (redness, mild discomfort), transient muscle aches, and occasional low-grade flushing or fatigue. Because the mechanism is immune activation, the theoretical concerns are different from suppressive drugs: it should be used with caution in people with active autoimmune disease (where amplifying T-cell and Th1 activity could in principle worsen the autoimmune process), in transplant recipients on intentional immunosuppression, and in pregnancy and breastfeeding (no adequate data). The Zadaxin label flags hypersensitivity reactions, and the COVID-19 cohort signal, worse non-recovery when given late in severe disease, is a reminder that 'immunomodulation' is not the same as 'always helpful'. Long-term safety beyond the studied 6–12 month treatment courses is poorly characterised, and the off-label research-chemical supply layers an unverified product on top of an unevidenced indication.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed by the MHRA. No UK marketing authorisation, no NHS provision, no regulated retail supply. Imported or compounded Tα1 used at private clinics is unlicensed; pharmacovigilance and patient protections do not apply.
- USNOT FDA-approved. Zadaxin has never received US marketing approval. Some compounding pharmacies have historically supplied Tα1 off-label; the FDA placed Tα1-class peptides under scrutiny in its 2023 Section 503A bulk-substance review and the regulatory window for compounded supply has narrowed.
- EUNo central EMA marketing authorisation exists for Zadaxin. Italy is the major exception: thymalfasin is licensed at national level and is available on prescription there. Outside Italy, the product is not generally licensed in EU member states.
- Rest of worldLicensed in approximately 35 countries, including China (a major market), Italy, several Latin American and South-East Asian jurisdictions. In those countries it is a prescription medicine, typically for chronic hepatitis B/C and selected cancer-adjunct indications.
- Sport
09 Clinical studies & research
Primary sources. Read the science yourself.